San Diego, CA -- (SBWIRE) -- 10/10/2016 -- Ariad Pharmaceuticals, Inc. is under investigation over potential securities laws violations. The investigation was announced on behalf of investors in NASDAQ:ARIA shares in connection certain financial statements made by Ariad Pharmaceuticals.

Investors who purchased shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On October 6, 2016, a report was published with the title "How Ariad Pharma Used a Safety Problem to Jack Up a Cancer Drug's Price," in which it described the conditions Ariad Pharmaceuticals, Inc allegedly used to up its price for the leukemia drug Iclusig. The article continued to say that after the U.S. Food and Drug Administration ("FDA") temporarily pulled Iclusig from the market, it did allow Iclusig to go back on the market with a reduced recommended dose and more restricted approved use. According to the article Ariad Pharmaceuticals, Inc then "embarked on a series of massive price increases" for its now-niche drug, "instead of reducing its price tag to reflect less benefit overall." On October 7, 2016 shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) closed at $13.40 per share.

Those who purchased shares of Ariad Pharmaceuticals, Inc. have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com